BridgeBio Pharma, Inc.
BBIO
Rang in aandelen
#1623
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Aandeelprijs
$67.78
Marktkapitalisatie
$13.25B
Verandering (1 dag)
-0.24%
Verandering (1 jaar)
20.47%
Land
US
Handel BridgeBio Pharma, Inc. (BBIO)
Categorie
Healthcare
Omzet van BridgeBio Pharma, Inc. (BBIO)
Omzet in Jun 2026 TTM: $713.07M
Volgens de laatste financiële rapporten van BridgeBio Pharma, Inc. bedraagt de huidige omzet van het bedrijf (TTM) $713.07M. In 2023 behaalde het bedrijf een omzet van $9.30M een daling ten opzichte van de omzet in het jaar 2022, die $77.65M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van BridgeBio Pharma, Inc. van 2017 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $713.07M | 221.35% |
| 2024 | $221.90M | 2,285.27% |
| 2023 | $9.30M | -88.02% |
| 2022 | $77.65M | 11.38% |
| 2021 | $69.72M | 745.14% |
| 2020 | $8.25M | -79.66% |
| 2019 | $40.56M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 1,670.41% |
US
|
|
| $2.23B | 212.45% |
US
|
|
| $15.74B | 2,107.96% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 744.42% |
NL
|
